FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Aleksandra Galetin

Research Profile

Chemicals & Drugs

Physiology

Concepts & Ideas

Anatomy

Phenomena

Metabolic Clearance Rate

Co-author Network

Publications

TOP 3
Katherine L Gill; J Brian Houston; Michael Gertz; Aleksandra Galetin
Application of a physiologically based pharmacokinetic model to assess propofol hepatic and renal glucuronidation in isolation: utility of in vitro and in vivo data.
Michael Gertz; Michael J Hobbs; J Brian Houston; KE Kenworthy; Malcolm Rowland; Catherine M Cartwright; Aleksandra Galetin
Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential.
Karelle Ménochet; J Brian Houston; KE Kenworthy; Aleksandra Galetin
Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Aleksandra Galetin (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Katherine L Gill; J Brian Houston; Michael Gertz; Aleksandra Galetin
Application of a physiologically based pharmacokinetic model to assess propofol hepatic and renal glucuronidation in isolation: utility of in vitro and in vivo data.
Drug metabolism and disposition: the biological fate of chemicals 2013;41(4):744-53.
2013: Michael Gertz; Michael J Hobbs; J Brian Houston; KE Kenworthy; Malcolm Rowland; Catherine M Cartwright; Aleksandra Galetin
Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential.
Pharmaceutical research 2013;30(3):761-80.
2012: Karelle Ménochet; J Brian Houston; KE Kenworthy; Aleksandra Galetin
Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes.
Drug metabolism and disposition: the biological fate of chemicals 2012;40(9):1744-56.
2012: Howard J Burt; Claire Collins; J Brian Houston; Ruth Hyland; Henry Pertinez; Carolina Säll; Aleksandra Galetin
Progress curve mechanistic modeling approach for assessing time-dependent inhibition of CYP3A4.
Drug metabolism and disposition: the biological fate of chemicals 2012;40(9):1658-67.
2012: Carolina Säll; J Brian Houston; Aleksandra Galetin
A comprehensive assessment of repaglinide metabolic pathways: impact of choice of in vitro system and relative enzyme contribution to in vitro clearance.
Drug metabolism and disposition: the biological fate of chemicals 2012;40(7):1279-89.
2012: Jane R Kenny; Carol Collins; Aleksandra Galetin; Sophie Mukadam; Suzanne Tay; Chenghong Zhang; S Cyrus Khojasteh
Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction.
Pharmaceutical research 2012;29(7):1960-76.
2012: Hannah M Jones; Sarah Kempshall; Emi Kimoto; Yurong Lai; Sonya C Tate; Hugh A Barton; Yi-An Bi; Ayman El-Kattan; Aleksandra Galetin; J Brian Houston; Katherine S Fenner
Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data.
Drug metabolism and disposition: the biological fate of chemicals 2012;40(5):1007-17.
2012: Katherine L Gill; J Brian Houston; Aleksandra Galetin
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
Drug metabolism and disposition: the biological fate of chemicals 2012;40(4):825-35.
2012: Karelle Ménochet; J Brian Houston; KE Kenworthy; Aleksandra Galetin
Simultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic model.
The Journal of pharmacology and experimental therapeutics 2012;341(1):2-15.
2012: Helen Graham; Owen Jones; Mike Walker; James Yates; Aleksandra Galetin; Leon Aarons
Comparison of in-vivo and in-silico methods used for prediction of tissue: plasma partition coefficients in rat.
The Journal of pharmacy and pharmacology 2012;64(3):383-96.
2011: Ian E Templeton; J Brian Houston; Aleksandra Galetin
Predictive utility of in vitro rifampin induction data generated in fresh and cryopreserved human hepatocytes, Fa2N-4, and HepaRG cells.
Drug metabolism and disposition: the biological fate of chemicals 2011;39(10):1921-9.
2011: Yoshiyuki Yabe; Aleksandra Galetin; J Brian Houston
Kinetic characterization of rat hepatic uptake of 16 actively transported drugs.
Drug metabolism and disposition: the biological fate of chemicals 2011;39(10):1808-14.
2011: Michael Gertz; J Brian Houston; Aleksandra Galetin
Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction.
Drug metabolism and disposition: the biological fate of chemicals 2011;39(9):1633-42.
2011: Helen E Cubitt; J Brian Houston; Aleksandra Galetin
Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data.
Drug metabolism and disposition: the biological fate of chemicals 2011;39(5):864-73.
2011: Eleanor J Guest; Leon Aarons; J Brian Houston; Amin Rostami-Hodjegan; Aleksandra Galetin
Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions.
Drug metabolism and disposition: the biological fate of chemicals 2011;39(2):170-3.
2011: Eleanor J Guest; Karen Rowland Yeo; Amin Rostami-Hodjegan; Geoffrey T Tucker; J Brian Houston; Aleksandra Galetin
Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models.
British journal of clinical pharmacology 2011;71(1):72-87.
2010: Michael Gertz; Anthony Harrison; J Brian Houston; Aleksandra Galetin
Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data.
Drug metabolism and disposition: the biological fate of chemicals 2010;38(7):1147-58.
2010: Howard J Burt; Aleksandra Galetin; J Brian Houston
IC50-based approaches as an alternative method for assessment of time-dependent inhibition of CYP3A4.
Xenobiotica; the fate of foreign compounds in biological systems 2010;40(5):331-43.
2010: Aleksandra Galetin; Michael Gertz; J Brian Houston
Contribution of intestinal cytochrome p450-mediated metabolism to drug-drug inhibition and induction interactions.
Drug metabolism and pharmacokinetics 2010;25(1):28-47.
2009: Raj Badhan; Jeffrey Penny; Aleksandra Galetin; J Brian Houston
Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption.
Journal of pharmaceutical sciences 2009;98(6):2180-97.
2009: Helen E Cubitt; J Brian Houston; Aleksandra Galetin
Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance.
Pharmaceutical research 2009;26(5):1073-83.
2008: J Brian Houston; Aleksandra Galetin
Methods for predicting in vivo pharmacokinetics using data from in vitro assays.
Current drug metabolism 2008;9(9):940-51.
2008: Michael Gertz; John D Davis; Anthony Harrison; J Brian Houston; Aleksandra Galetin
Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations.
Current drug metabolism 2008;9(8):785-95.
2008: Verawan Uchaipichat; Aleksandra Galetin; J Brian Houston; Peter I Mackenzie; J Andrew Williams; John O Miners
Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by udp-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites.
Molecular pharmacology 2008;74(4):1152-62.
2008: Aleksandra Galetin; Michael Gertz; J Brian Houston
Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions.
Expert opinion on drug metabolism & toxicology 2008;4(7):909-22.
2008: Jamie Henshall; Aleksandra Galetin; Anthony Harrison; J Brian Houston
Comparative analysis of CYP3A heteroactivation by steroid hormones and flavonoids in different in vitro systems and potential in vivo implications.
Drug metabolism and disposition: the biological fate of chemicals 2008;36(7):1332-40.
2008: Peter J Kilford; Michael Gertz; J Brian Houston; Aleksandra Galetin
Hepatocellular binding of drugs: correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data.
Drug metabolism and disposition: the biological fate of chemicals 2008;36(7):1194-7.
2008: Laura K Hinton; Aleksandra Galetin; J Brian Houston
Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions.
Pharmaceutical research 2008;25(5):1063-74.
2008: David Hallifax; Aleksandra Galetin; J Brian Houston
Prediction of metabolic clearance using fresh human hepatocytes: comparison with cryopreserved hepatocytes and hepatic microsomes for five benzodiazepines.
Xenobiotica; the fate of foreign compounds in biological systems 2008;38(4):353-67.
2008: Michael Gertz; Peter J Kilford; J Brian Houston; Aleksandra Galetin
Drug lipophilicity and microsomal protein concentration as determinants in the prediction of the fraction unbound in microsomal incubations.
Drug metabolism and disposition: the biological fate of chemicals 2008;36(3):535-42.
2007: Aleksandra Galetin
Intestinal first-pass metabolism: bridging the gap between in vitro and in vivo.
Current drug metabolism 2007;8(7):643-4.
2007: Aleksandra Galetin; Laura K Hinton; Howard Burt; R Scott Obach; J Brian Houston
Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs.
Current drug metabolism 2007;8(7):685-93.
2006: Aleksandra Galetin; J Brian Houston
Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism.
The Journal of pharmacology and experimental therapeutics 2006;318(3):1220-9.
2006: Hayley S Brown; Aleksandra Galetin; David Hallifax; J Brian Houston
Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Clinical pharmacokinetics 2006;45(10):1035-50.
2006: Aleksandra Galetin; Howard Burt; Laura Gibbons; J Brian Houston
Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition.
Drug metabolism and disposition: the biological fate of chemicals 2006;34(1):166-75.
2005: Hayley S Brown; Kiyomi Ito; Aleksandra Galetin; J Brian Houston
Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant.
British journal of clinical pharmacology 2005;60(5):508-18.
2005: Aleksandra Galetin; Kiyomi Ito; David Hallifax; J Brian Houston
CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions.
The Journal of pharmacology and experimental therapeutics 2005;314(1):180-90.
2005: Helen C Rawden; David J Carlile; A Tindall; David Hallifax; Aleksandra Galetin; Kiyomi Ito; J Brian Houston
Microsomal prediction of in vivo clearance and associated interindividual variability of six benzodiazepines in humans.
Xenobiotica; the fate of foreign compounds in biological systems 2005;35(6):603-25.
2005: J Brian Houston; Aleksandra Galetin
Modelling atypical CYP3A4 kinetics: principles and pragmatism.
Archives of biochemistry and biophysics 2005;433(2):351-60.
2004: Aleksandra Galetin; Caroline Brown; David Hallifax; Kiyomi Ito; J Brian Houston
Utility of recombinant enzyme kinetics in prediction of human clearance: impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates.
Drug metabolism and disposition: the biological fate of chemicals 2004;32(12):1411-20.
2004: Verawan Uchaipichat; Peter I Mackenzie; Xiao-Hui Guo; Dione A Gardner-Stephen; Aleksandra Galetin; J Brian Houston; John O Miners
Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid.
Drug metabolism and disposition: the biological fate of chemicals 2004;32(4):413-23.
2003: J Brian Houston; Aleksandra Galetin
Progress towards prediction of human pharmacokinetic parameters from in vitro technologies.
Drug metabolism reviews 2003;35(4):393-415.
2003: Aleksandra Galetin; Stephen E Clarke; J Brian Houston
Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine.
Drug metabolism and disposition: the biological fate of chemicals 2003;31(9):1108-16.
2003: Andrew N Stone; Peter I Mackenzie; Aleksandra Galetin; J Brian Houston; John O Miners
Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7.
Drug metabolism and disposition: the biological fate of chemicals 2003;31(9):1086-9.
2002: Aleksandra Galetin; Stephen E Clarke; J Brian Houston
Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(12):1512-22.